These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24019032)

  • 21. Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
    Santos RD; Watts GF
    Lancet; 2015 Jan; 385(9965):307-10. PubMed ID: 25282517
    [No Abstract]   [Full Text] [Related]  

  • 22. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapy: PCSK9 inhibitors for treating familial hypercholesterolaemia.
    Mabuchi H; Nohara A
    Nat Rev Endocrinol; 2015 Jan; 11(1):8-9. PubMed ID: 25404016
    [No Abstract]   [Full Text] [Related]  

  • 24. Lipid-lowering study raises issues of therapy's value.
    Thompson CA
    Am J Health Syst Pharm; 2008 Apr; 65(7):594-5. PubMed ID: 18359962
    [No Abstract]   [Full Text] [Related]  

  • 25. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How far down to push the LDL cholesterol? PCSK9 where statins fail.
    Simko V; Ginter E
    Bratisl Lek Listy; 2016; 117(4):193-4. PubMed ID: 27075380
    [No Abstract]   [Full Text] [Related]  

  • 27. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia.
    Grundy SM
    Nat Rev Cardiol; 2016 Feb; 13(2):74-5. PubMed ID: 26763537
    [No Abstract]   [Full Text] [Related]  

  • 28. PCSK9 inhibitors for LDL lowering.
    Walsh JP
    Trends Cardiovasc Med; 2015 Oct; 25(7):575-7. PubMed ID: 25990014
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.
    Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):49-56. PubMed ID: 22208355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dyslipidaemia: Evolocumab lowers LDL cholesterol.
    Huynh K
    Nat Rev Cardiol; 2014 Dec; 11(12):687. PubMed ID: 25331087
    [No Abstract]   [Full Text] [Related]  

  • 32. [PCSK9 inhibitors: new treatment to lower cholesterol].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simvastatin + ezetimibe: a combination with no proven advantages.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
    [No Abstract]   [Full Text] [Related]  

  • 34. Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.
    Stamerra CA; Di Giosia P; Giorgini P; De Feo M; Grassi D; Ferri C; Sahebkar A
    J Neurosci Res; 2018 May; 96(5):762-764. PubMed ID: 29152786
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 38. The ezetimibe Jonah: the trials and tribulations of an unlucky drug.
    Wierzbicki AS
    Int J Clin Pract; 2011 Dec; 65(12):1207-8. PubMed ID: 21951808
    [No Abstract]   [Full Text] [Related]  

  • 39. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
    Filardi PP; Paolillo S; Trimarco B
    G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD
    N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.